AstraZeneca to send direct mail for Toprol-XL

Share this article:
AstraZeneca will send out direct-mail communications as part of a larger campaign for its hypertension drug, Toprol-XL, following reports of name confusion between the treatment and other Rx brands. The overall program launch's audience will include pharmacists and pharmacy technicians, physicians, physician assistants, nurse practitioners, nurses and patients.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions